These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

846 related items for PubMed ID: 27180926

  • 1. Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.
    van de Kerkhof PC, Griffiths CE, Reich K, Leonardi CL, Blauvelt A, Tsai TF, Gong Y, Huang J, Papavassilis C, Fox T.
    J Am Acad Dermatol; 2016 Jul; 75(1):83-98.e4. PubMed ID: 27180926
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials.
    Sticherling M, Nikkels AF, Hamza AM, Kwong P, Szepietowski JC, El Sayed M, Ghislain PD, Khotko AA, Patekar M, Ortmann CE, Forrer P, Papanastasiou P, Keefe D.
    Am J Clin Dermatol; 2023 Sep; 24(5):821-835. PubMed ID: 37341961
    [Abstract] [Full Text] [Related]

  • 4. Secukinumab in plaque psoriasis--results of two phase 3 trials.
    Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C, ERASURE Study Group, FIXTURE Study Group.
    N Engl J Med; 2014 Jul 24; 371(4):326-38. PubMed ID: 25007392
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies.
    Körber A, Papavassilis C, Bhosekar V, Reinhardt M.
    Drugs Aging; 2018 Feb 24; 35(2):135-144. PubMed ID: 29404966
    [Abstract] [Full Text] [Related]

  • 6. Secukinumab (AIN457) for the treatment of psoriasis.
    López-Ferrer A, Vilarrasa E, Puig L.
    Expert Rev Clin Immunol; 2015 Feb 24; 11(11):1177-88. PubMed ID: 26428036
    [Abstract] [Full Text] [Related]

  • 7. Meta-analysis of the Efficacy and Safety of Secukinumab for the Treatment of Plaque Psoriasis.
    Ryoo JY, Yang HJ, Ji E, Yoo BK.
    Ann Pharmacother; 2016 May 24; 50(5):341-51. PubMed ID: 26783352
    [Abstract] [Full Text] [Related]

  • 8. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.
    Deodhar A, Mease PJ, McInnes IB, Baraliakos X, Reich K, Blauvelt A, Leonardi C, Porter B, Das Gupta A, Widmer A, Pricop L, Fox T.
    Arthritis Res Ther; 2019 May 02; 21(1):111. PubMed ID: 31046809
    [Abstract] [Full Text] [Related]

  • 9. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
    Thaçi D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, Ziv M, Pinter A, Hugot S, You R, Milutinovic M.
    J Am Acad Dermatol; 2015 Sep 02; 73(3):400-9. PubMed ID: 26092291
    [Abstract] [Full Text] [Related]

  • 10. Safety of secukinumab in the treatment of psoriasis.
    Blauvelt A.
    Expert Opin Drug Saf; 2016 Oct 02; 15(10):1413-20. PubMed ID: 27545070
    [Abstract] [Full Text] [Related]

  • 11. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
    Rich P, Sigurgeirsson B, Thaci D, Ortonne JP, Paul C, Schopf RE, Morita A, Roseau K, Harfst E, Guettner A, Machacek M, Papavassilis C.
    Br J Dermatol; 2013 Feb 02; 168(2):402-11. PubMed ID: 23362969
    [Abstract] [Full Text] [Related]

  • 12. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE).
    Paul C, Lacour JP, Tedremets L, Kreutzer K, Jazayeri S, Adams S, Guindon C, You R, Papavassilis C, JUNCTURE study group.
    J Eur Acad Dermatol Venereol; 2015 Jun 02; 29(6):1082-90. PubMed ID: 25243910
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
    Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P, Haemmerle S, Thurston HJ, Papavassilis C, Richards HB.
    Br J Dermatol; 2013 Feb 02; 168(2):412-21. PubMed ID: 23106107
    [Abstract] [Full Text] [Related]

  • 14. Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept.
    Strober B, Gottlieb AB, Sherif B, Mollon P, Gilloteau I, McLeod L, Fox T, Mordin M, Gnanasakthy A, Papavassilis C, Lebwohl MG.
    J Am Acad Dermatol; 2017 Apr 02; 76(4):655-661. PubMed ID: 28087133
    [Abstract] [Full Text] [Related]

  • 15. Secukinumab Self-Administration by Prefilled Syringe Maintains Reduction of Plaque Psoriasis Severity Over 52 Weeks: Results of the FEATURE Trial.
    Gottlieb AB, Blauvelt A, Prinz JC, Papanastasiou P, Pathan R, Nyirady J, Fox T, Papavassilis C.
    J Drugs Dermatol; 2016 Oct 01; 15(10):1226-1234. PubMed ID: 27741340
    [Abstract] [Full Text] [Related]

  • 16. Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data.
    Strober B, Leonardi C, Papp KA, Mrowietz U, Ohtsuki M, Bissonnette R, Ferris LK, Paul C, Lebwohl M, Braun DK, Mallbris L, Wilhelm S, Xu W, Ljungberg A, Acharya N, Reich K.
    J Am Acad Dermatol; 2017 Mar 01; 76(3):432-440.e17. PubMed ID: 27889292
    [Abstract] [Full Text] [Related]

  • 17. Secukinumab: a review in moderate to severe plaque psoriasis.
    Garnock-Jones KP.
    Am J Clin Dermatol; 2015 Aug 01; 16(4):323-330. PubMed ID: 26202871
    [Abstract] [Full Text] [Related]

  • 18. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.
    Papp KA, Griffiths CE, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, Chan D, Hsu MC, Ho V, Ghislain PD, Strober B, Reich K, PHOENIX 1 Investigators, PHOENIX 2 Investigators, ACCEPT Investigators.
    Br J Dermatol; 2013 Apr 01; 168(4):844-54. PubMed ID: 23301632
    [Abstract] [Full Text] [Related]

  • 19. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.
    Ohtsuki M, Morita A, Abe M, Takahashi H, Seko N, Karpov A, Shima T, Papavassilis C, Nakagawa H, ERASURE Study Japanese subgroup.
    J Dermatol; 2014 Dec 01; 41(12):1039-46. PubMed ID: 25354738
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.